Spinal Fusion

The company grew 45% in 1Q21 despite surgical volume pressure in January and February as ATEC continues to drive conversion and uptake.

The company realized around 40% of its first-quarter sales in March to overcome COVID and weather-related declines for 1Q21.

These companies recently received notable FDA 510(k) clearances, funding or launched products and studies. We highlight robotics/digital, spine and orthobiologic applications.

The company grew +9% in 2020 despite the pandemic, buoyed by reimbursement wins and an innovative approach to drive surgeon adoption.

The company capped 2020 with record revenues in the fourth quarter, and expects that momentum to continue in 2021.

The company grew +28% in 2020 despite the pandemic and expects to grow another +25% in 2021 as it continues building clinical distinction.

Zimmer Biomet announced it will spin off its spine and dental businesses into a new public company while it focuses on priority markets.

The fourth quarter of 2020 brought a dramatic surge in the pandemic that further depressed orthopedic surgical volumes worldwide.

With its renewed focus on winning market share, Medtronic estimates Mazor X placements outpaced Globus Medical's ExcelsiusGPS by a factor of 1.5 in 3Q20.

The company grew nearly 26% for 3Q20, driven by continuing favorable coverage policies in the U.S. and backlogged procedures in July.

The company grew +10% in 3Q20, driven by U.S. spinal implant sales strengthened by new product introductions and robotics pull-through.

CEO Nick Deeter says that 95% of children continue to receive adult orthopedic products that were never intended for them nor cleared by FDA for use in children. WishBone seeks to change the paradigm of pediatric orthopedics with its child-focused implants and sterile packaged disposable kits.

Eeric Truumees, M.D., First Vice President of NASS' Board of Directors, is optimistic that the online virtual annual meeting event in October will allow attendees to benefit from broader input in smaller doses.

The company's exposure in global markets caused revenue declines of -24% in 1H20, but MicroPort launched several new products to spur future growth

The company grew in the high single digits for 1H20 as it benefited from provincial procurement tenders and the acquisition of Libeier.

The company earned its seventh consecutive double-digit growth quarter in 2Q20 as it continued to drive clinical distinction and surgeon adoption.

The company's sales accelerated through 2Q20 and grew in the high single digits in July, but it cautioned that the new patient pipeline could slow in 2H20.

The company exited 2Q20 with double-digit growth that accelerated to the mid-teens in July as new products and competitive rep hiring drove share gains.

The company believes patient backlogs contributed significantly to volume acceleration observed in 2Q20, while new patient volumes remain depressed.

The company exited June 2020 with revenues up +42% compared to the prior year as it benefitted from a backlog of procedures rescheduled in March and April.

Patient sentiment and confidence will play a key role in the COVID-19 orthopedic procedure recovery. What can we learn about patients from the data?

NuVasive suffered modest impact from COVID-19 in 1Q20 and expects severe reductions in 2Q. However, the company is using its strong cash position to push forward with product development.

The company grew in the low double digits in 1Q20 but was on pace for record procedure volumes before COVID-19 impacted the U.S. orthopedic market in mid-March.

DePuy Synthes declined 7.5% in 1Q20 due to the impact of the COVID-19 pandemic, with the worst expected to come in 2Q as procedures are deferred en masse.

Driven by additional favorable reimbursement decisions from payers and an expanding sales force, SI-BONE grew 22% in 2019.

With 12 new product launches and improvement across all major growth metrics, ATEC drove 24% growth in 2019 as it continues to reinvent itself.

Improving MIS adoption and new products drove NuVasive's growth in 2019 but the company also announced the launch of its Pulse system will be delayed.

Despite supply issues in biologics and flat enabling technology sales, Globus had record revenues in 4Q and a third consecutive year of double-digit growth.

In October 2019 we met with leaders from Globus Medical to discuss their acquisition of StelKast and entry into the joint replacement market.